Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.51 |
| ▸ | NPY1R | P25929 | 2/20 | 0.51 |
| ▸ | NPY4R | P50391 | 2/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30836857 | 0.92 | BACE1 (0.55) | BACE1NPY5RNPY1RNPY4RPTPN1 | |
| SCHEMBL30866942 | 0.92 | NPY4R (0.55) | BACE1NPY5RNPY1RNPY4R | |
| SCHEMBL30215487 | 0.90 | BACE1 (0.57) | BACE1NPY5RNPY1RNPY4RBACE2 | |
| SCHEMBL29670260 | 0.89 | TFPI (0.56) | BACE1NPY5RNPY1RNPY4R | |
| SCHEMBL30198602 | 0.88 | TFPI (0.56) | BACE1NPY5RNPY1RNPY4RBACE2 | |
| SCHEMBL30345254 | 0.88 | NPY4R (0.58) | BACE1NPY5RNPY1RNPY4R | |
| SCHEMBL30956315 | 0.88 | NPY4R (0.51) | BACE1NPY5RNPY1RNPY4R | |
| SCHEMBL30198934 | 0.88 | BACE1 (0.52) | BACE1NPY5RNPY1RNPY4R | |
| SCHEMBL30799751 | 0.88 | BACE1 (0.53) | BACE1NPY5RNPY1RNPY4RPTPN1 | |
| SCHEMBL30175904 | 0.87 | BACE1 (0.58) | BACE1NPY5RNPY1RNPY4RBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | disclosed |